GCGiovanni Ciana

Giovanni Ciana

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Giovanni Ciana has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical follow-up in a group of Gaucher type I patients switching enzyme replacement therapy from imiglucerase to velaglucerase

    by Bruno Bembi, Annalisa Sechi, Andrea Dardis, Laura Deroma, Daniela Macor, Giulia Liva, Giovanni Ciana

  • Did the Temporary Shortage in Supply of Imiglucerase Have Clinical Consequences? Retrospective Observational Study on 34 Italian Gaucher Type I Patients

    by Laura Deroma, Annalisa Sechi, Andrea Dardis, Daniela Macor, Giulia Liva, Giovanni Ciana, Bruno Bembi

    Background. Enzyme Replacement Therapy (ERT) is the standard of care in Gaucher disease. The effects of withdrawal or reduced doses are debated, thus a retrospective cohort study was conducted to investigate clinical and laboratory differences in 34 Gaucher type 1 patients experiencing an ERT dosage reduction after the forced temporary imiglucerase shortage in 2009. Methods. Haemoglobin concentration, leukocytes and platelets counts, and chitotriosidase activity were assessed at baseline and after 6 and 12 months (t0, t6, t12), while bone pain, energy, work or school performance, concentration, memory and social life every 3 months. Results. The cohort was made up of 18 males and 16 females (medians: age 41.8 years, therapy duration 14.1 years, dosage reduction 35.5%). Haemoglobin, leukocytes and platelets remained substantially stable, while chitotriosidase activity showed an increase, especially after t6. Age, splenectomy or genotype were not associated with laboratory parameters changes, except for a significant median increase of chitotriosidase activity in non-splenectomised patients after 12 months ( p = 0.01). At 3, 6, 9 and 12 months, more than 50% patients reported at least one problem in subjective well-being (56%, 65%, 70%, 58%, respectively), while bone pain occurred or worsened in 13/33, 13/32, 7/28 and 5/26 patients, respectively. No bone crises were reported. Conclusions. Drug reduction did not induce substantial modification in the laboratory values but seems to have influenced the well-being perception of some Gaucher patients. Thus, bone pain, general health and quality of life should be carefully monitored during ERT reductions.


  • Long‐term bone mineral density response to enzyme replacement therapy in a retrospective pediatric cohort of Gaucher patients

    by Giovanni Ciana, Laura Deroma, Anna Martina Franzil, Andrea Dardis, Bruno Bembi

    Osteopenia is described as a relevant sign of bone involvement in Gaucher disease (GD) both in pediatric and adult patients. Furthermore, abnormal bone metabolism is considered to play a role in growth and pubertal delay. To analyze the long‐term effect of enzyme replacement therapy (ERT) on bone mineral density (BMD), a retrospective observational study was conducted in a cohort of 18 GD pediatric patients (13 males, 5 females; median age 9.2 years). They received biweekly infusions of 20‐60 IU/kg of alglucerase/imiglucerase. Clinical, laboratory and imaging parameters were evaluated every 2 years. According to the International Society of Clinical Densitometry guidelines, a Z‐score ≤ ‐2.0 was considered pathological. Nine patients (group P0) began ERT during infancy and nine (group P1) during puberty. At baseline, in three patients (16.6 %; 1P0, 2P1) Z‐score was ≤ ‐2.0 (range ‐2.47 to ‐2.25). In patient P0 it normalized after 2 years, while in the 2P1 patients (splenectomized siblings) it persisted abnormal. The remaining 15 patients (83.4 %) always presented a normal value. In group P0, Z‐score improved in infancy but showed a significant decrease during puberty, on the contrary it constantly improved in group P1. Furthermore, at baseline group P0 showed a higher median Z‐score than group P1: 0.79 (0.38; 1.50) and ‐1.61 (‐2.25; ‐1.56) respectively. The use of correct BMD standards to interpret bone loss during pediatric age suggests a limited significance of bone loss in these patients. Moreover, the persistence of residual disease activity may affect normal bone growth during puberty in GD populations.


  • Open Access

    Premature Birth with Complicated Perinatal Course Delaying Diagnosis of Prader-Willi Syndrome

    by G. Ciana, M. C. Fertz, V. Pecile, S. Demarini

    Prader-Willi syndrome in the newborn is essentially characterized by marked hypotonia, feeding difficulties, hypogonadism, and possible characteristic facial features. However, diagnosis at this age may be particularly difficult, and dysmorphic features may be subtle or absent. Prematurity can furthermore delay clinical features recognition and typical complications due to preterm birth may contribute to divert the diagnosis. We describe a preterm baby with a complicated perinatal course later diagnosed as PWS.


  • Biochemical and molecular findings in a patient with myoclonic epilepsy due to a mistarget of the β-glucosidase enzyme

    by Andrea Dardis, Mirella Filocamo, Serena Grossi, Giovanni Ciana, Silvana Franceschetti, Silvia Dominissini, Guido Rubboli, Maya Di Rocco, Bruno Bembi


  • Audiological findings in Gaucher's disease

    by Domenico Leonardo Grasso, Veronica Ileana Guerci, Giorgio Pelos, Giovanni Ciana, Flavio Ciarafoni, Elisabetta Zocconi, Bruno Bembi

    Gaucher's disease (GD), the most common lysosomal storage disease, is an autosomal recessive, multi-systemic glycosphingolipid disorder. It is caused by reduced activity of the enzyme glucocerebrosidase, a lysosomal acid β-glucosidase, which results in the accumulation of glucosylceramide in lysosomes of the monocyte-macrophage system. Audiological assessment of GD patients has been performed in previous studies. Auditory brainstem response (ABR) still remains the main tool to evaluate the involvement of the auditory pathway in the progression of disease. Nevertheless, the relationship between abnormal findings and brainstem involvement remains unclear. We report our data and review the scientific literature.